Treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma with lymphoblastoid interferon

A. Rios, P. W A Mansell, G. R. Newell, J. M. Reuben, Evan M Hersh, J. U. Gutterman

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Twelve homosexual patients with Kaposi's sarcoma associated with the acquired immune deficiency syndrome (AIDS) were treated with a preparation of purified human lymphoblastoid interferon (Wellferon [Burroughs Wellcome, Research Triangle Park, NC]). They were given a dose of 20 x 106 U/m2 intramuscularly daily for approximately two months. Responders continued their treatment on a maintenance schedule of 20 x 106 U/m2 three times a week. Four patients experienced complete remissions, and four experienced partial remissions that resulted in a total response rate of 67%. The median duration of treatment was 14 weeks (7 to 28+ weeks), and the median response duration was 28+ weeks (19 to 29+ weeks). Of the four patients in complete remission, one relapsed at 25 weeks and one at 26 weeks; the other two remained in complete remission of 28 and 29 weeks. The clinical toxicity consisted of chills, fever, fatigue, and asthenia. Hematologic toxicity was similar to that previously described for other preparations of α-interferon and consisted of moderate leukopenia and thrombocytopenia. Asthenia, a condition present in all 12 patients, was severe in 50%. A minimal tumor burden, the absence of circulating interferon before treatment, and a performance status of ≥90% on the Karnofsky scale were related to an improved response rate. Measurement of immunologic parameters showed significant declines in the already impaired T cell levels, lymphocyte blastogenic response to concanavalin A, monocyte-mediated antibody-dependent cellular cytotoxicity, and monocyte-adherence. Activation of natural killer cells was not noted, and no life-threatening infections occurred during treatment. These data suggest that human lymphoblastoid interferon is an active agent in the treatment of Kaposi's sarcoma, and its use warrants further study in a large number of patients.

Original languageEnglish (US)
Pages (from-to)506-512
Number of pages7
JournalJournal of Clinical Oncology
Volume3
Issue number4
StatePublished - 1985
Externally publishedYes

Fingerprint

Kaposi's Sarcoma
Interferon-alpha
Acquired Immunodeficiency Syndrome
Asthenia
Interferons
Monocytes
Therapeutics
Karnofsky Performance Status
Chills
Leukopenia
Concanavalin A
Tumor Burden
Natural Killer Cells
Thrombocytopenia
Fatigue
Appointments and Schedules
Fever
Maintenance
Lymphocytes
T-Lymphocytes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Rios, A., Mansell, P. W. A., Newell, G. R., Reuben, J. M., Hersh, E. M., & Gutterman, J. U. (1985). Treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma with lymphoblastoid interferon. Journal of Clinical Oncology, 3(4), 506-512.

Treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma with lymphoblastoid interferon. / Rios, A.; Mansell, P. W A; Newell, G. R.; Reuben, J. M.; Hersh, Evan M; Gutterman, J. U.

In: Journal of Clinical Oncology, Vol. 3, No. 4, 1985, p. 506-512.

Research output: Contribution to journalArticle

Rios, A, Mansell, PWA, Newell, GR, Reuben, JM, Hersh, EM & Gutterman, JU 1985, 'Treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma with lymphoblastoid interferon', Journal of Clinical Oncology, vol. 3, no. 4, pp. 506-512.
Rios, A. ; Mansell, P. W A ; Newell, G. R. ; Reuben, J. M. ; Hersh, Evan M ; Gutterman, J. U. / Treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma with lymphoblastoid interferon. In: Journal of Clinical Oncology. 1985 ; Vol. 3, No. 4. pp. 506-512.
@article{010333cfdfba4b9385403b8b798051b0,
title = "Treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma with lymphoblastoid interferon",
abstract = "Twelve homosexual patients with Kaposi's sarcoma associated with the acquired immune deficiency syndrome (AIDS) were treated with a preparation of purified human lymphoblastoid interferon (Wellferon [Burroughs Wellcome, Research Triangle Park, NC]). They were given a dose of 20 x 106 U/m2 intramuscularly daily for approximately two months. Responders continued their treatment on a maintenance schedule of 20 x 106 U/m2 three times a week. Four patients experienced complete remissions, and four experienced partial remissions that resulted in a total response rate of 67{\%}. The median duration of treatment was 14 weeks (7 to 28+ weeks), and the median response duration was 28+ weeks (19 to 29+ weeks). Of the four patients in complete remission, one relapsed at 25 weeks and one at 26 weeks; the other two remained in complete remission of 28 and 29 weeks. The clinical toxicity consisted of chills, fever, fatigue, and asthenia. Hematologic toxicity was similar to that previously described for other preparations of α-interferon and consisted of moderate leukopenia and thrombocytopenia. Asthenia, a condition present in all 12 patients, was severe in 50{\%}. A minimal tumor burden, the absence of circulating interferon before treatment, and a performance status of ≥90{\%} on the Karnofsky scale were related to an improved response rate. Measurement of immunologic parameters showed significant declines in the already impaired T cell levels, lymphocyte blastogenic response to concanavalin A, monocyte-mediated antibody-dependent cellular cytotoxicity, and monocyte-adherence. Activation of natural killer cells was not noted, and no life-threatening infections occurred during treatment. These data suggest that human lymphoblastoid interferon is an active agent in the treatment of Kaposi's sarcoma, and its use warrants further study in a large number of patients.",
author = "A. Rios and Mansell, {P. W A} and Newell, {G. R.} and Reuben, {J. M.} and Hersh, {Evan M} and Gutterman, {J. U.}",
year = "1985",
language = "English (US)",
volume = "3",
pages = "506--512",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - Treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma with lymphoblastoid interferon

AU - Rios, A.

AU - Mansell, P. W A

AU - Newell, G. R.

AU - Reuben, J. M.

AU - Hersh, Evan M

AU - Gutterman, J. U.

PY - 1985

Y1 - 1985

N2 - Twelve homosexual patients with Kaposi's sarcoma associated with the acquired immune deficiency syndrome (AIDS) were treated with a preparation of purified human lymphoblastoid interferon (Wellferon [Burroughs Wellcome, Research Triangle Park, NC]). They were given a dose of 20 x 106 U/m2 intramuscularly daily for approximately two months. Responders continued their treatment on a maintenance schedule of 20 x 106 U/m2 three times a week. Four patients experienced complete remissions, and four experienced partial remissions that resulted in a total response rate of 67%. The median duration of treatment was 14 weeks (7 to 28+ weeks), and the median response duration was 28+ weeks (19 to 29+ weeks). Of the four patients in complete remission, one relapsed at 25 weeks and one at 26 weeks; the other two remained in complete remission of 28 and 29 weeks. The clinical toxicity consisted of chills, fever, fatigue, and asthenia. Hematologic toxicity was similar to that previously described for other preparations of α-interferon and consisted of moderate leukopenia and thrombocytopenia. Asthenia, a condition present in all 12 patients, was severe in 50%. A minimal tumor burden, the absence of circulating interferon before treatment, and a performance status of ≥90% on the Karnofsky scale were related to an improved response rate. Measurement of immunologic parameters showed significant declines in the already impaired T cell levels, lymphocyte blastogenic response to concanavalin A, monocyte-mediated antibody-dependent cellular cytotoxicity, and monocyte-adherence. Activation of natural killer cells was not noted, and no life-threatening infections occurred during treatment. These data suggest that human lymphoblastoid interferon is an active agent in the treatment of Kaposi's sarcoma, and its use warrants further study in a large number of patients.

AB - Twelve homosexual patients with Kaposi's sarcoma associated with the acquired immune deficiency syndrome (AIDS) were treated with a preparation of purified human lymphoblastoid interferon (Wellferon [Burroughs Wellcome, Research Triangle Park, NC]). They were given a dose of 20 x 106 U/m2 intramuscularly daily for approximately two months. Responders continued their treatment on a maintenance schedule of 20 x 106 U/m2 three times a week. Four patients experienced complete remissions, and four experienced partial remissions that resulted in a total response rate of 67%. The median duration of treatment was 14 weeks (7 to 28+ weeks), and the median response duration was 28+ weeks (19 to 29+ weeks). Of the four patients in complete remission, one relapsed at 25 weeks and one at 26 weeks; the other two remained in complete remission of 28 and 29 weeks. The clinical toxicity consisted of chills, fever, fatigue, and asthenia. Hematologic toxicity was similar to that previously described for other preparations of α-interferon and consisted of moderate leukopenia and thrombocytopenia. Asthenia, a condition present in all 12 patients, was severe in 50%. A minimal tumor burden, the absence of circulating interferon before treatment, and a performance status of ≥90% on the Karnofsky scale were related to an improved response rate. Measurement of immunologic parameters showed significant declines in the already impaired T cell levels, lymphocyte blastogenic response to concanavalin A, monocyte-mediated antibody-dependent cellular cytotoxicity, and monocyte-adherence. Activation of natural killer cells was not noted, and no life-threatening infections occurred during treatment. These data suggest that human lymphoblastoid interferon is an active agent in the treatment of Kaposi's sarcoma, and its use warrants further study in a large number of patients.

UR - http://www.scopus.com/inward/record.url?scp=0021924090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021924090&partnerID=8YFLogxK

M3 - Article

C2 - 3872349

AN - SCOPUS:0021924090

VL - 3

SP - 506

EP - 512

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 4

ER -